EVO (EVO) Q1 2026: Double-Digit D&PD Order Growth Sets Up H2 Recovery Amid Strategic Review
EVO’s first quarter showed double-digit order growth in D&PD, but operating softness and margin pressure persisted as the company invests ahead of expected H2 improvement. Strategic review and the Horizon operating model reset signal a pivot toward tech and scientific leadership, while management’s full-year guidance assumes accelerating contributions from strategic partnerships and AI-driven demand. Investors should monitor the timing of recovery in preclinical spending and the impact of ongoing cost initiatives on profitability trajectory.
Summary
- D&PD Order Momentum: New sales in Discovery & Preclinical Development saw double-digit growth, supporting the case for H2 acceleration.
- Strategic Reset Underway: Launch of the Horizon operating model and an ongoing strategic review reflect a focus on repositioning core capabilities.
- Profitability Inflection Needed: Margin pressure and Q1 investment weigh on results, with improvement expected as strategic partnerships ramp.
Business Overview
EVO operates as a contract research and drug discovery partner, providing integrated scientific services and technology platforms to pharmaceutical, biotech, and AI-first companies. The company’s major segments include Discovery & Preclinical Development (D&PD), which focuses on early-stage research and milestone-driven collaborations, and JEP, its licensing and partnership business. Revenue is generated through a mix of research fees, milestone payments, and strategic partnership deals, with a growing emphasis on technology-enabled drug discovery for both traditional pharma and emerging AI-driven clients.
Performance Analysis
EVO’s Q1 performance was marked by a strong order intake in D&PD, with double-digit year-over-year growth in new sales. However, revenue and profitability were weighed down by investment activity and the timing of milestone payments, resulting in a quarter that management characterized as a trough for operating performance. The company emphasized that Q1’s lower profitability was anticipated as part of a broader investment cycle, positioning EVO to capture upcoming contract wins and strategic partnership opportunities in the second half of the year.
While seasonality typically favors Q4, management downplayed its impact relative to milestone timing, noting that recent years have also seen strong Q4 contributions but cautioning against overemphasizing this pattern. The persistent softness in preclinical spending, particularly among biotech clients, continues to be a headwind, though internal indicators such as a decline in project cancellations and stabilization in biotech funding suggest a gradual path to recovery. FX headwinds and a negative impact from JEP licensing were also cited as factors shaping the H1 versus H2 dynamic.
- D&PD Order Intake Strength: Double-digit growth in new sales signals underlying demand even as revenue recognition lags.
- Profitability Compression: Q1 margin pressure reflects upfront investment, with management expecting normalization as strategic deals close in H2.
- Milestone Timing Volatility: Revenue and profit swings are increasingly driven by the timing of milestone and partnership payments, not seasonality alone.
Management reaffirmed full-year guidance, implicitly requiring a step-up in both revenue and EBITDA in the back half, with strategic partnerships and AI-related demand expected to contribute meaningfully to the recovery.
Executive Commentary
"First of all, when I look at Q1, order intake in D&PD versus a year ago, we're double digit up. So that tells you that it has been a good quarter in terms of new sales...from a revenue profile perspective, the events around milestones have a bigger impact than the seasonality."
Unknown, Chief Financial Officer
"We are not offering kind of an AI service line. Usually it's part of our drug discovery capabilities and platforms, so it becomes part of it...our cyber tax business has benefited from that most recently, and we expect this to further benefit."
Unknown, Chief Financial Officer
Strategic Positioning
1. Horizon Operating Model Reset
In March, EVO announced its Horizon operating model, a structural overhaul designed to align the company with its revised vision of technological and scientific leadership. This reset aims to sharpen core competencies, streamline operations, and better position EVO for growth in both traditional and AI-driven drug discovery markets.
2. Strategic Review Initiation
The initiation of a formal strategic review is not in response to external activist pressure or inbound interest, according to management. Instead, it is a logical next step following last year’s reset and the Horizon launch, aimed at optimizing the business for long-term value creation and operational excellence.
3. AI-Driven Demand Integration
AI-first companies are increasingly turning to EVO’s platforms for integrated drug discovery solutions. While EVO does not offer a standalone AI service line, AI capabilities are embedded in its offerings, with the cyber tax business already benefiting from this trend. Management expects further incremental demand from this segment, though such contributions are bundled within broader partnership packages.
4. Strategic Partnerships as Growth Engine
Management’s full-year guidance assumes a ramp in strategic partnership activity in H2, with a pipeline of opportunities under active negotiation. These deals are expected to drive both top-line and margin improvement, offsetting ongoing FX and licensing headwinds in JEP.
Key Considerations
The quarter’s results underscore a company in strategic transition, balancing near-term operating softness with a pipeline of growth levers tied to technology, partnerships, and internal efficiency. Investors must weigh the lag between order intake and revenue recognition, the volatility of milestone payments, and the timing of cost savings from the Horizon model as they assess the path to profitability.
Key Considerations:
- Order Book Health: D&PD’s double-digit order growth provides a leading indicator for future revenue, but conversion timing remains uncertain.
- Milestone and Licensing Volatility: Revenue and profitability are increasingly sensitive to the timing of partnership and milestone payments, creating quarter-to-quarter noise.
- AI Adoption Embedded in Offerings: AI-driven demand is materializing, but quantifying its standalone impact is challenging due to integration within broader solutions.
- Strategic Review Outcomes: The ongoing review could result in portfolio adjustments, further operational streamlining, or new capital allocation priorities.
Risks
EVO faces continued risk from delayed recovery in preclinical spending, particularly if biotech funding remains tepid or project cancellations reaccelerate. The company’s reliance on milestone-driven revenue introduces volatility, while FX headwinds and licensing declines in JEP could offset gains from strategic partnerships. Execution risk around the Horizon model and the strategic review is elevated, as the timing and magnitude of cost savings and growth initiatives remain uncertain. Investors should also watch for potential competitive encroachment as AI-enabled platforms proliferate across the sector.
Forward Outlook
For Q2 2026, EVO guided to:
- Continued order strength in D&PD, with revenue and EBITDA expected to gradually improve as investments convert to contract wins.
- Persistent FX and licensing headwinds, partially offset by cost savings from the Horizon model.
For full-year 2026, management maintained guidance:
- Revenue and EBITDA growth weighted to H2, driven by strategic partnership ramp and underlying D&PD growth.
Management highlighted several factors that will shape the outlook:
- Milestone and partnership deal timing will drive quarter-to-quarter swings, with Q4 likely to be seasonally strong but not the sole driver of annual performance.
- Strategic review and Horizon execution are expected to deliver incremental margin improvement as the year progresses.
Takeaways
Investors face a transition quarter where strategic initiatives and order growth are yet to translate into margin and profit expansion.
- Order Intake Outpaces Revenue Recognition: D&PD’s robust order book signals future growth, but near-term results remain volatile due to milestone timing and investment ramp.
- Strategic Review and Horizon Model Execution: The company is betting on operational realignment and portfolio optimization to unlock value, but execution and timing risks persist.
- AI and Strategic Partnerships as Catalysts: Embedded AI capabilities and a growing pipeline of strategic deals are positioned as the next phase of growth, with investors needing to monitor conversion rates and partnership economics in H2 and beyond.
Conclusion
EVO’s Q1 2026 results highlight a business in strategic flux, with double-digit order growth offset by margin compression and milestone timing volatility. The company’s reset via the Horizon model and a formal strategic review signal a commitment to long-term value creation, but near-term profitability hinges on execution and the successful ramp of strategic partnerships in the second half. Investors should track the interplay between order momentum, milestone conversion, and cost discipline as the year unfolds.
Industry Read-Through
EVO’s experience this quarter echoes broader industry trends in contract research and drug discovery, where milestone-driven revenue and AI integration are reshaping business models. The persistent lag between order intake and revenue recognition, combined with funding volatility in biotech, is a dynamic likely to affect peers. The shift toward embedding AI within core offerings rather than standalone services reflects evolving client expectations and competitive pressures. For the sector, the strategic emphasis on operational resets and portfolio reviews underscores the need for agility as scientific and technological disruptions accelerate. Investors in the CRO and drug discovery space should expect continued volatility and a premium on execution and partnership conversion.